MDG1015 clinical trial in solid tumors to be paused
“Medigene has continuously prioritized projects and optimized the allocation of our resources to the R&D work and programs that we believe create the most value for patients and shareholders. While we have successfully advanced our lead TCR-T therapy MDG1015 to IND approval, we have decided to delay the MDG1015 clinical trial and pause all further development of our other autologous cell therapy programs, whilst we continue to seek future financing and partnerships to re-initiate their further development. This enables us to keep our strategic options open while focusing near term on our ability to generate 3S TCRs for TCR-guided therapies, and in advancing our TCR-guided T cell engager (TCR-TCE) MDG3010 program in collaboration with WuXi Biologics,” said Selwyn Ho, CEO at Medigene.
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us